Shilpa Medicare Limited , a prominent player in the pharmaceutical sector, has reported its highest quarterly revenue and EBITDA in Q2, demonstrating significant growth and strategic advancements.

Financial Highlights

Shilpa Medicare achieved remarkable financial results in Q2:

• Record quarterly revenue of INR 372.00 crores, representing a 7% year-over-year growth
• Highest-ever quarterly EBITDA of INR 110.00 crores
• EBITDA margins expanded to 30%, up from 26% in the previous year
• For H1, revenue grew 8% to INR 700.00 crores
• H1 EBITDA increased 20% to INR 208.00 crores

Segment Performance

API Segment

• Drove growth with a 14% quarterly increase
• Growth attributed to commercialization of expanded capacities and key base business products

Formulations Business

• Reported 16% revenue growth
• Key products gained US market share through partners

Strategic Initiatives and Product Pipeline

• Preparing to launch NorUDCA in Q3, India's first-in-class therapy for NAFLD
• Strategic partnerships formed with three Indian companies for NorUDCA launch
• In biologics, two Novel Biologic Entity projects expected to enter human studies

Regulatory Achievements

• Filed 23 new DMFs across markets in H1
• Received 36 new approvals in the first half

Corporate Actions

Bonus Share Issue

The company has approved the allotment of 9,77,90,908 bonus equity shares in a 1:1 ratio, potentially enhancing shareholder value and improving stock liquidity.

Divestment in Joint Venture

Shilpa Medicare has entered into an agreement to sell a 31% stake in its joint venture, Sravathi Advance Process Technologies, for INR 4,960.05 lakhs. This strategic move may allow the company to focus on its core business areas.

Exceptional Losses

The company recorded exceptional losses of INR 156.64 lakhs in its standalone financials, primarily attributed to provisions for impairment on foreign subsidiary advances and investments.

Outlook

Shilpa Medicare's record-breaking quarterly performance, coupled with strategic initiatives and product pipeline developments, positions the company for potential continued growth. The expansion in revenue and EBITDA margins suggests that the company's business strategies are yielding positive results. The upcoming launch of NorUDCA and advancements in biologics projects indicate promising future prospects.

However, investors should note the exceptional losses related to foreign subsidiaries, which may require monitoring in future quarters. The company's ability to maintain this growth trajectory, successfully integrate its strategic decisions, and capitalize on its product pipeline will be key factors to watch in the coming periods.

Shilpa Medicare Limited , a prominent Indian pharmaceutical company, has successfully completed a significant corporate action through a postal ballot process. The company announced that its shareholders have approved the reclassification of two promoter group members to the public category.

Key Details of the Reclassification

The postal ballot, which ran from October 9 to November 8, 2025, sought shareholder approval for two ordinary resolutions:

1. Reclassification of Mr. Suraj Kumar Inani from the "Promoter group" category to the "Public" category
2. Reclassification of Ms. Priya Inani from the "Promoter group" category to the "Public" category

Both resolutions passed with an overwhelming majority, receiving over 97% votes in favor.

Voting Process and Timeline

The scrutinizer confirmed that the voting process was conducted fairly and transparently, in accordance with regulatory requirements.

Implications and Compliance

This reclassification aligns with the regulatory framework set by the Securities and Exchange Board of India (SEBI) for the reclassification of promoter group members. It reflects Shilpa Medicare's commitment to maintaining transparency in its shareholding structure and adhering to corporate governance best practices.

The company has duly informed the stock exchanges - BSE Limited and the National Stock Exchange of India Limited - about the results of the postal ballot, in compliance with Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

As Shilpa Medicare continues to focus on its core pharmaceutical business, including the development of APIs, formulations, and biologics across various therapeutic segments, this corporate action demonstrates the company's proactive approach to shareholder engagement and regulatory compliance.

Investors and market watchers may view this development as part of Shilpa Medicare's ongoing efforts to streamline its ownership structure, potentially impacting the company's governance dynamics going forward.